Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:28:11 EST Fri 06 Feb 2026
Enter Symbol
or Name
USA
CA



Q:XNCR - XENCOR INC - https://www.xencor.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
XNCR - Q0.17.00·18.460.111.61+0.797.3630.16,9865,37711.14  11.65  11.0118.69  6.9216:10:05Jan 0815 min RT 2¢

Recent Trades - Last 10 of 5377
Time ETExPriceChangeVolume
16:10:05Q11.610.791
16:10:04Q11.610.791
16:10:04Q11.610.791
16:08:13Q11.610.796,688
16:06:09Q11.610.7913,715
16:04:43Q11.610.791
16:04:23Q11.610.791
16:04:13Q11.610.791
16:02:46Q11.610.79329
16:02:34Q11.610.791,706

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-08 08:01U:XNCRNews ReleaseXencor Highlights Corporate Priorities and 2026 Pipeline Milestones
2025-12-09 07:00U:XNCRNews ReleaseXencor Announces Extension of U.S. Patent Term on Certain Xtend(TM) Antibodies
2025-11-10 16:01U:XNCRNews ReleaseXencor to Participate at Upcoming Investor Conferences
2025-11-05 16:01U:XNCRNews ReleaseXencor Reports Third Quarter 2025 Financial Results
2025-10-24 12:30U:XNCRNews ReleaseXencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
2025-10-21 08:01U:XNCRNews ReleaseXencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
2025-10-14 12:45U:XNCRNews ReleaseXencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2025-08-27 16:01U:XNCRNews ReleaseXencor to Participate at Upcoming Investor Conferences
2025-08-06 16:01U:XNCRNews ReleaseXencor Reports Second Quarter 2025 Financial Results
2025-07-31 16:01U:XNCRNews ReleaseXencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
2025-05-07 16:01U:XNCRNews ReleaseXencor Reports First Quarter 2025 Financial Results
2025-04-29 16:01U:XNCRNews ReleaseXencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
2025-03-13 16:01U:XNCRNews ReleaseXencor Appoints Todd Simpson to Board of Directors
2025-02-27 08:01U:XNCRNews ReleaseXencor Reports Fourth Quarter and Full Year 2024 Financial Results